These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
    Author: Yu G, Liang X, Xie X, Su M, Zhao S.
    Journal: Int J Cardiol; 2001 Dec; 81(2-3):123-9; discussion 129-30. PubMed ID: 11744126.
    Abstract:
    This study was designed to investigate diverse effects of angiotensin II (AngII) type I receptor antagonists, losartan, angiotensin converting enzyme (ACE) inhibitors, fosinopril, and calcium channel blockade, amlodipine on cardiomyocyte apoptosis and AngII in the left ventricle of spontaneously hypertensive rats (SHR). The SHRs were randomized to four groups: SHR-L (treated with losartan, 30 mg x kg(-1) x d(-1)), SHR-F (with fosinopril, 10 mg x kg(-1) x d(-1)), SHR-A (with amlodipine, 10 mg x kg(-1) x d(-1)) and SHR-C (with placebo). The cardiomyocyte apoptosis was examined by in situ TDT-mediated dUTP nick end labeling, AngII concentrations of plasma and myocardium were measured by radio immunoassay at 8 and 16 weeks of the study respectively. The results showed that: (1) compared with SHR-C at 8 and 16 weeks respectively; the systolic blood pressure was decreased similarly in the three treatment groups. Left ventricular weight and mass indexes were reduced in the three treatment groups. The latter parameter at 16 weeks was lower in SHR-F than that in the other two treatment groups. (2) Compared with SHR-C, the cardiomyocyte apoptotic index (APOI) was reduced significantly at 8 weeks only in SHR-F, and at 16 weeks in all three treatment groups. The APOI of SHR-F was lowest among the three treatment groups examined at latter endpoint. (3) Compared with SHR-C at both endpoints of this study, plasma and myocardium AngII levels were increased in SHR-L. However, plasma AngII concentrations were not altered in SHR-F and SHR-A, myocardium AngII concentrations were reduced significantly at 8 weeks only in SHR-F, and at 16 weeks in SHR-F and SHR-A. Meanwhile, myocardium AngII in SHR-F at 16 weeks was lower than that in SHR-A. The results of this study indicate that losartan, fosinopril, and amlodipine each effectively reverses heart hypertrophy and inhibits cardiomyocyte apoptosis, and fosinopril may be most effective in these cardioprotective effects. These findings suggest that the effects of the three blockers on myocardiocyte apoptosis and left ventricular hypertrophy were related to inhibition of the myocardium rennin-angiotensin-aldsterone system.
    [Abstract] [Full Text] [Related] [New Search]